Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
15.41
-0.71 (-4.40%)
At close: Aug 28, 2026, 4:00 PM EDT
15.16
-0.25 (-1.62%)
After-hours: Aug 28, 2026, 7:54 PM EDT
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,141,755
Market Cap
2.33B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Vera Therapeutics | 361 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 305 |
| Harmony Biosciences Holdings | 293 |
| Kodiak Sciences | 141 |
| Mesoblast | 108 |
| Rapport Therapeutics | 84 |
BHVN News
- 3 days ago - H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’ - TheFly
- 3 days ago - Biohaven rises 10.8% - TheFly
- 3 days ago - Biohaven price target lowered to $30 from $50 at Raymond James - TheFly
- 3 days ago - Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact - TheFly
- 4 days ago - Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million - Reuters
- 4 days ago - Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy - PRNewsWire
- 4 days ago - Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University - PRNewsWire
- 12 days ago - Biohaven price target raised to $19 from $18 at Morgan Stanley - TheFly